FAM72B and cancer: Meanwhile, utilizing the GEPIA2.0 database with the median FAM72B expression value as the threshold, our analysis revealed that OS and recurrence-free survival (RFS) were both decreased in cancers with elevated FAM72B expression in ACC, KIRP, LGG, LIHC, and SARC, suggesting a correlation between high FAM72B expression and adverse prognosis in these cancers (Figure S1A–J).